[Effect of tumor promoting agents on the in vitro malignant transformation of the fetal rat brain cells exposed in utero to ethylnitrosourea]. 1984

T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto

The potent tumor promoter 12-0-tetradecanoyl phorbol 13-acetate (TPA) and phenobarbital (PB) were tested for their abilities to promote effect of these agents on the in vitro malignant transformation of the fetal rat brain cells exposed in utero to Ethylnitrosourea (ENU). Rat fetal brain cells were transferred to cultured system at 72 hours after single pulse of ENU (50 mg/kg B. W.) to pregnant SD-JCL rats on the 18th day of gestation. Primary cultured cells were divided into 20 groups, and graded doses of PB from 1.0 mM to 5.0 mM or that of TPA from 0.1 ng/ml to 50.0 ng/ml were added continuously into cultured medium. In the ENU group treated with TPA, it was found the results of more early appearance of "piled up focus" for about 90 days, more early capacity of colony formation in semisolid soft agar for about 110 days, and more early appearance of tumorigenicity for about 90 days than that in the ENU groups treated with or without acetone. An increased agglutinability to Concanavalin A (200 micrograms/ml) was appeared more early in the ENU groups treated with TPA than in the ENU groups. On the basis of these results, it is suggested that TPA promoted the in vitro malignant transformation of the fetal rat brain cells with a transplacental carcinogen of ENU, and TPA might effect as a tumor promoter on the neurogenic carcinogenesis. As for the mechanisms of the promoting effect of TPA, it is speculated that TPA might modulate the function of cell membrane from the results of Concanavalin A agglutinability, and might modulate the differentiation on cell function from the results of morphological analysis.

UI MeSH Term Description Entries
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010704 Phorbols The parent alcohol of the tumor promoting compounds from CROTON OIL (Croton tiglium). Tigliane,Tiglianes
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug

Related Publications

T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
March 1986, Cancer research,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
February 1981, Neurologia medico-chirurgica,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
November 1975, Journal of the National Cancer Institute,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
September 1977, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
December 1979, Cancer letters,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
May 1980, Journal of the National Cancer Institute,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
June 1976, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
January 1965, Marseille chirurgical,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
July 1995, Neurochemical research,
T Kokunai, and Kazuyoshi, and Korosue, and K Taomoto, and N Tamaki, and S Matsumoto
October 1978, British journal of experimental pathology,
Copied contents to your clipboard!